Nuzenio

Tipranks Relay Therapeutics

Tipranks Relay Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Timeline

Fri, 07 Aug 2026 21:23:12 GMTRelay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts - TipRanks
Fri, 07 Aug 2026 13:45:51 GMTBoris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward - TipRanks
Fri, 07 Aug 2026 09:48:14 GMTRelay Therapeutics price target raised to $30 from $27 at Barclays - TipRanks
Fri, 07 Aug 2026 09:43:38 GMTAnalyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029 - TipRanks
Fri, 07 Aug 2026 09:26:23 GMTTD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating - Moomoo
Thu, 06 Aug 2026 21:11:52 GMTRelay Therapeutics Expands ATM Equity Offering Agreement - TipRanks

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tipranks Relay Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.